|
Apr 30
|
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
|
|
Apr 2
|
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
|
|
Mar 31
|
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
|
|
Mar 27
|
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
|
|
Feb 14
|
Is Nanobiotix (NBTX) the Best Nanotech Penny Stock to Invest In?
|
|
Feb 12
|
Voting Rights and Shares Capital of the Company
|